Loading...
Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients
Treatment of metastatic kidney cancer has changed dramatically in the past years with the use of VEGF-targeted therapies and mTOR inhibitors. However, resistance occurs. We report here two cases of patients who benefited, both on disease control and side effects, from the addition of bevacizumab to...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
S. Karger AG
2011
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3237108/ https://ncbi.nlm.nih.gov/pubmed/22171218 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000334581 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|